MicroRNA‐based therapies: Revolutionizing the treatment of acute myeloid leukemia
MicroRNAs (miRNAs) are small noncoding epigenetic regulators that exert critical significance by influencing target mRNAs and governing gene expression patterns and cellular signaling pathways. miRNAs play a pivotal role in a wide array of biological processes, including cell differentiation, prolif...
Gespeichert in:
| Veröffentlicht in: | International journal of laboratory hematology 2024-02, Vol.46 (1), p.33-41 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 41 |
|---|---|
| container_issue | 1 |
| container_start_page | 33 |
| container_title | International journal of laboratory hematology |
| container_volume | 46 |
| creator | Chandraprabha Vineetha, Radhakrishnan Anitha Geetha Raj, John Devipriya, Padmakumar Sreelatha Mahitha, Mohanan Hariharan, Sreedharan |
| description | MicroRNAs (miRNAs) are small noncoding epigenetic regulators that exert critical significance by influencing target mRNAs and governing gene expression patterns and cellular signaling pathways. miRNAs play a pivotal role in a wide array of biological processes, including cell differentiation, proliferation, and survival. Numerous miRNAs contribute to tumorigenesis and cancer progression by promoting tumor growth, angiogenesis, invasion, and immune evasion, while others exert tumor suppressive effects. From a clinical perspective, it has been demonstrated that numerous miRNAs are related to the prognosis in acute myeloid leukemia (AML) patients. They hold the potential to be utilized as biomarkers, aiding in improved treatment decision‐making. Moreover, a number of preclinical investigations have offered compelling evidence to create novel treatment approaches that target miRNAs in AML. This review highlights the clinical significance of miRNAs in the diagnosis, prognosis, and treatment response of adult patients with AML. |
| doi_str_mv | 10.1111/ijlh.14211 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2903323122</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2915869006</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3931-c8b6f8ad0274ab119871881e26964296ea3c7fae35dbba26b37ed8025116c8df3</originalsourceid><addsrcrecordid>eNp9kM1Kw0AQgBdRbK1efAAJeBEhdWc32Wy8laK2UhWqgrewSSZ2a35qNlHqyUfwGX0SU6M9eHAvszAfH8NHyD7QPjTvRM_TWR8cBrBBuuC5YLsuf9hc_xl0yI4xc0pdz6H-NulwCdTljtMlt1c6Kovp9eDz_SNUBmOrmmGpFhrNqTXFlyKtK13k-k3nj6uVVZWoqgzzyioSS0V1hVa2xLTQsZVi_YSZVrtkK1Gpwb2f2SP352d3w5E9ubkYDwcTO-I-BzuSoUikiinzHBUC-NIDKQGZ8IXDfIGKR16ikLtxGComQu5hLClzAUQk44T3yFHrXZTFc42mCjJtIkxTlWNRm4D5lHPGgbEGPfyDzou6zJvrGgpcKXxKRUMdt1STxJgSk2BR6kyVywBosEodrFIH36kb-OBHWYcZxmv0t20DQAu86hSX_6iC8eVk1Eq_ALVUiWg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2915869006</pqid></control><display><type>article</type><title>MicroRNA‐based therapies: Revolutionizing the treatment of acute myeloid leukemia</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Chandraprabha Vineetha, Radhakrishnan ; Anitha Geetha Raj, John ; Devipriya, Padmakumar ; Sreelatha Mahitha, Mohanan ; Hariharan, Sreedharan</creator><creatorcontrib>Chandraprabha Vineetha, Radhakrishnan ; Anitha Geetha Raj, John ; Devipriya, Padmakumar ; Sreelatha Mahitha, Mohanan ; Hariharan, Sreedharan</creatorcontrib><description>MicroRNAs (miRNAs) are small noncoding epigenetic regulators that exert critical significance by influencing target mRNAs and governing gene expression patterns and cellular signaling pathways. miRNAs play a pivotal role in a wide array of biological processes, including cell differentiation, proliferation, and survival. Numerous miRNAs contribute to tumorigenesis and cancer progression by promoting tumor growth, angiogenesis, invasion, and immune evasion, while others exert tumor suppressive effects. From a clinical perspective, it has been demonstrated that numerous miRNAs are related to the prognosis in acute myeloid leukemia (AML) patients. They hold the potential to be utilized as biomarkers, aiding in improved treatment decision‐making. Moreover, a number of preclinical investigations have offered compelling evidence to create novel treatment approaches that target miRNAs in AML. This review highlights the clinical significance of miRNAs in the diagnosis, prognosis, and treatment response of adult patients with AML.</description><identifier>ISSN: 1751-5521</identifier><identifier>EISSN: 1751-553X</identifier><identifier>DOI: 10.1111/ijlh.14211</identifier><identifier>PMID: 38105344</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Acute myeloid leukemia ; Angiogenesis ; cancer ; Cell differentiation ; Cell survival ; cytogenetics ; Decision making ; Epigenetics ; Gene expression ; microRNA ; miRNA ; Patients ; Prognosis ; Tumorigenesis</subject><ispartof>International journal of laboratory hematology, 2024-02, Vol.46 (1), p.33-41</ispartof><rights>2023 John Wiley & Sons Ltd.</rights><rights>2024 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3931-c8b6f8ad0274ab119871881e26964296ea3c7fae35dbba26b37ed8025116c8df3</citedby><cites>FETCH-LOGICAL-c3931-c8b6f8ad0274ab119871881e26964296ea3c7fae35dbba26b37ed8025116c8df3</cites><orcidid>0000-0002-1107-4692</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fijlh.14211$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fijlh.14211$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38105344$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chandraprabha Vineetha, Radhakrishnan</creatorcontrib><creatorcontrib>Anitha Geetha Raj, John</creatorcontrib><creatorcontrib>Devipriya, Padmakumar</creatorcontrib><creatorcontrib>Sreelatha Mahitha, Mohanan</creatorcontrib><creatorcontrib>Hariharan, Sreedharan</creatorcontrib><title>MicroRNA‐based therapies: Revolutionizing the treatment of acute myeloid leukemia</title><title>International journal of laboratory hematology</title><addtitle>Int J Lab Hematol</addtitle><description>MicroRNAs (miRNAs) are small noncoding epigenetic regulators that exert critical significance by influencing target mRNAs and governing gene expression patterns and cellular signaling pathways. miRNAs play a pivotal role in a wide array of biological processes, including cell differentiation, proliferation, and survival. Numerous miRNAs contribute to tumorigenesis and cancer progression by promoting tumor growth, angiogenesis, invasion, and immune evasion, while others exert tumor suppressive effects. From a clinical perspective, it has been demonstrated that numerous miRNAs are related to the prognosis in acute myeloid leukemia (AML) patients. They hold the potential to be utilized as biomarkers, aiding in improved treatment decision‐making. Moreover, a number of preclinical investigations have offered compelling evidence to create novel treatment approaches that target miRNAs in AML. This review highlights the clinical significance of miRNAs in the diagnosis, prognosis, and treatment response of adult patients with AML.</description><subject>Acute myeloid leukemia</subject><subject>Angiogenesis</subject><subject>cancer</subject><subject>Cell differentiation</subject><subject>Cell survival</subject><subject>cytogenetics</subject><subject>Decision making</subject><subject>Epigenetics</subject><subject>Gene expression</subject><subject>microRNA</subject><subject>miRNA</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Tumorigenesis</subject><issn>1751-5521</issn><issn>1751-553X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kM1Kw0AQgBdRbK1efAAJeBEhdWc32Wy8laK2UhWqgrewSSZ2a35qNlHqyUfwGX0SU6M9eHAvszAfH8NHyD7QPjTvRM_TWR8cBrBBuuC5YLsuf9hc_xl0yI4xc0pdz6H-NulwCdTljtMlt1c6Kovp9eDz_SNUBmOrmmGpFhrNqTXFlyKtK13k-k3nj6uVVZWoqgzzyioSS0V1hVa2xLTQsZVi_YSZVrtkK1Gpwb2f2SP352d3w5E9ubkYDwcTO-I-BzuSoUikiinzHBUC-NIDKQGZ8IXDfIGKR16ikLtxGComQu5hLClzAUQk44T3yFHrXZTFc42mCjJtIkxTlWNRm4D5lHPGgbEGPfyDzou6zJvrGgpcKXxKRUMdt1STxJgSk2BR6kyVywBosEodrFIH36kb-OBHWYcZxmv0t20DQAu86hSX_6iC8eVk1Eq_ALVUiWg</recordid><startdate>202402</startdate><enddate>202402</enddate><creator>Chandraprabha Vineetha, Radhakrishnan</creator><creator>Anitha Geetha Raj, John</creator><creator>Devipriya, Padmakumar</creator><creator>Sreelatha Mahitha, Mohanan</creator><creator>Hariharan, Sreedharan</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1107-4692</orcidid></search><sort><creationdate>202402</creationdate><title>MicroRNA‐based therapies: Revolutionizing the treatment of acute myeloid leukemia</title><author>Chandraprabha Vineetha, Radhakrishnan ; Anitha Geetha Raj, John ; Devipriya, Padmakumar ; Sreelatha Mahitha, Mohanan ; Hariharan, Sreedharan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3931-c8b6f8ad0274ab119871881e26964296ea3c7fae35dbba26b37ed8025116c8df3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acute myeloid leukemia</topic><topic>Angiogenesis</topic><topic>cancer</topic><topic>Cell differentiation</topic><topic>Cell survival</topic><topic>cytogenetics</topic><topic>Decision making</topic><topic>Epigenetics</topic><topic>Gene expression</topic><topic>microRNA</topic><topic>miRNA</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Tumorigenesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chandraprabha Vineetha, Radhakrishnan</creatorcontrib><creatorcontrib>Anitha Geetha Raj, John</creatorcontrib><creatorcontrib>Devipriya, Padmakumar</creatorcontrib><creatorcontrib>Sreelatha Mahitha, Mohanan</creatorcontrib><creatorcontrib>Hariharan, Sreedharan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of laboratory hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chandraprabha Vineetha, Radhakrishnan</au><au>Anitha Geetha Raj, John</au><au>Devipriya, Padmakumar</au><au>Sreelatha Mahitha, Mohanan</au><au>Hariharan, Sreedharan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MicroRNA‐based therapies: Revolutionizing the treatment of acute myeloid leukemia</atitle><jtitle>International journal of laboratory hematology</jtitle><addtitle>Int J Lab Hematol</addtitle><date>2024-02</date><risdate>2024</risdate><volume>46</volume><issue>1</issue><spage>33</spage><epage>41</epage><pages>33-41</pages><issn>1751-5521</issn><eissn>1751-553X</eissn><abstract>MicroRNAs (miRNAs) are small noncoding epigenetic regulators that exert critical significance by influencing target mRNAs and governing gene expression patterns and cellular signaling pathways. miRNAs play a pivotal role in a wide array of biological processes, including cell differentiation, proliferation, and survival. Numerous miRNAs contribute to tumorigenesis and cancer progression by promoting tumor growth, angiogenesis, invasion, and immune evasion, while others exert tumor suppressive effects. From a clinical perspective, it has been demonstrated that numerous miRNAs are related to the prognosis in acute myeloid leukemia (AML) patients. They hold the potential to be utilized as biomarkers, aiding in improved treatment decision‐making. Moreover, a number of preclinical investigations have offered compelling evidence to create novel treatment approaches that target miRNAs in AML. This review highlights the clinical significance of miRNAs in the diagnosis, prognosis, and treatment response of adult patients with AML.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38105344</pmid><doi>10.1111/ijlh.14211</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-1107-4692</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1751-5521 |
| ispartof | International journal of laboratory hematology, 2024-02, Vol.46 (1), p.33-41 |
| issn | 1751-5521 1751-553X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2903323122 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Acute myeloid leukemia Angiogenesis cancer Cell differentiation Cell survival cytogenetics Decision making Epigenetics Gene expression microRNA miRNA Patients Prognosis Tumorigenesis |
| title | MicroRNA‐based therapies: Revolutionizing the treatment of acute myeloid leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T12%3A52%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MicroRNA%E2%80%90based%20therapies:%20Revolutionizing%20the%20treatment%20of%20acute%20myeloid%20leukemia&rft.jtitle=International%20journal%20of%20laboratory%20hematology&rft.au=Chandraprabha%20Vineetha,%20Radhakrishnan&rft.date=2024-02&rft.volume=46&rft.issue=1&rft.spage=33&rft.epage=41&rft.pages=33-41&rft.issn=1751-5521&rft.eissn=1751-553X&rft_id=info:doi/10.1111/ijlh.14211&rft_dat=%3Cproquest_cross%3E2915869006%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2915869006&rft_id=info:pmid/38105344&rfr_iscdi=true |